Genelux Corporation (GNLX) Insider Trading

Over the last 3 months, GNLX insiders made 0 open-market buys and 11 sales, a net sale of -$57K (SEC Form 4). Over the last 6 months, 38 institutions increased and 26 reduced their position (13F).

Insider Activity

Sentiment
0/100
Buys (3m)
0
Sells (3m)
11
Net (3m)
-$57.5K
Insider trades by month Buys Sells
Dec
May
Dec
Mar
May
Jun
Context3-month price +14.5%Institutions accumulating (13F)
DateInsiderTypeSharesPrice
Jun 4, 2026Smalling Ralphofficer: Head of RegulatorySell192$2.93
Jun 2, 2026Thomas JohndirectorSell10,000$2.98
May 12, 2026Smalling Ralphofficer: Head of RegulatorySell270$2.98
May 12, 2026Yu Yongofficer: Chief Scientific OfficerSell605$2.97
May 12, 2026Cappello Josephofficer: Chief Technical OfficerSell605$2.97
May 12, 2026Zindrick Thomasofficer: President and CEOSell2,798$2.94
Mar 26, 2026Smalling Ralphofficer: Head of RegulatorySell240$2.51
Mar 26, 2026Smalling Ralphofficer: Head of RegulatorySell345$2.42
Mar 26, 2026Zindrick Thomasofficer: President and CEOSell3,582$2.42
Mar 26, 2026Cappello Josephofficer: Chief Technical OfficerSell906$2.42
Mar 26, 2026Yu Yongofficer: SVP, Clinical DevelopmentSell906$2.42
Mar 3, 2026Thomas JohndirectorSell10,000$2.90
Jan 7, 2026Litten Jasonofficer: Chief Medical OfficerGrant275,000$4.55
Dec 11, 2025Zindrick Thomasofficer: President and CEOSell4,509$5.37
Dec 11, 2025Yu Yongofficer: SVP, Clinical DevelopmentSell973$5.37
Dec 11, 2025Yu Yongofficer: SVP, Clinical DevelopmentSell3,219$3.36
Dec 11, 2025Zindrick Thomasofficer: President and CEOSell12,673$3.33
Dec 11, 2025Cappello Josephofficer: Chief Technical OfficerSell1,270$3.33
Dec 11, 2025Cappello Josephofficer: Chief Technical OfficerSell1,463$3.36
Dec 11, 2025Cappello Josephofficer: Chief Technical OfficerSell973$5.37
Dec 9, 2025Smalling Ralphofficer: Head of RegulatorySell1,244$3.36
Dec 9, 2025Smalling Ralphofficer: Head of RegulatorySell580$3.36
Dec 9, 2025Smalling Ralphofficer: Head of RegulatorySell165$4.69
Dec 9, 2025Smalling Ralphofficer: Head of RegulatorySell343$5.37
Dec 2, 2025Thomas JohndirectorSell10,000$5.00
Sep 3, 2025Yu Yongofficer: SVP, Clinical DevelopmentGrant65,000$3.33
Sep 3, 2025Yu Yongofficer: SVP, Clinical DevelopmentGrant207,652$3.33
Sep 3, 2025Zindrick Thomasdirector, officer: President and CEOGrant23,568$3.33
Sep 3, 2025Zindrick Thomasdirector, officer: President and CEOGrant925,000$3.33
Sep 3, 2025Zindrick Thomasdirector, officer: President and CEOGrant250,000$3.33

Source: GNLX SEC Form 4 filings, latest Jun 4, 2026. For informational purposes only — not investment advice.

Institutional activity (13F)

How institutions changed their GNLX positions over the last 6 months (SEC Form 13F).

Increased
38
New positions
31
Reduced
26
Sold out
17
Largest moves
InstitutionActionSharesFiled
WOODWARD DIVERSIFIED CAPITAL, LLCIncreased2.1MApr 24, 2026
WOODWARD DIVERSIFIED CAPITAL, LLCIncreased1.9MJan 14, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position1.7MMay 15, 2026
VANGUARD GROUP INCIncreased1.6MJan 29, 2026
BLEICHROEDER LPIncreased1.4MMay 14, 2026
BLEICHROEDER LPUnchanged714KFeb 13, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased454KMay 15, 2026
BLACKROCK, INC.Increased406KMay 13, 2026
BLACKROCK, INC.Increased385KFeb 12, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased381KFeb 9, 2026
BANK OF AMERICA CORP /DE/Increased336KFeb 17, 2026
BANK OF AMERICA CORP /DE/Reduced324KMay 18, 2026
BANK OF AMERICA CORP /DE/Reduced323KFeb 3, 2026
FLPUTNAM INVESTMENT MANAGEMENT COIncreased303KFeb 9, 2026
ALYESKA INVESTMENT GROUP, L.P.Unchanged285KFeb 13, 2026

Source: SEC Form 13F filings. For informational purposes only — not investment advice.

← Back to GNLX overview (price, financials, earnings)